Skip to main content
TipRanks
Go Ultimate75% OFF

NewAmsterdam Pharma Company (NAMS) Stock Statistics & Valuation Metrics

292 Followers

Total Valuation

NewAmsterdam Pharma Company has a market cap or net worth of $2.42B. The enterprise value is $2.39B.

Market Cap
$2.42B
Enterprise Value
$2.39B

Share Statistics

NewAmsterdam Pharma Company has 119,930,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
119,930,000
Owned by Insiders
0.37%
Owned by Institutions
42.60%

Financial Efficiency

NewAmsterdam Pharma Company’s return on equity (ROE) is -0.30 and return on invested capital (ROIC) is -33.01%.

Return on Equity (ROE)
-0.30
Return on Assets (ROA)
-0.26
Return on Invested Capital (ROIC)
-33.01%
Return on Capital Employed (ROCE)
-0.33
Revenue Per Employee
225.03K
Profits Per Employee
-2.04M
Employee Count
100
Asset Turnover
0.03
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of NewAmsterdam Pharma Company is -11.78. NewAmsterdam Pharma Company’s PEG ratio is -1.43.

PE Ratio
-11.78
PS Ratio
93.13
PB Ratio
3.96
Price to FCF
-16.01
Price to Operating Cash Flow
-16.62
PEG Ratio
-1.43

Income Statement

In the last 12 months, NewAmsterdam Pharma Company had revenue of 22.50M and earned -203.82M in profits. Earnings per share was -1.75.

Revenue
22.50M
Gross Profit
22.44M
Operating Income
-225.68M
Pretax Income
-203.82M
Net Income
-203.82M
EBITDA
-242.32M
Earnings Per Share (EPS)
-1.75

Cash Flow

In the last 12 months, operating cash flow was -150.47M and capital expenditures -395,000, giving a free cash flow of -150.86M billion.

Operating Cash Flow
-150.47M
Free Cash Flow
-150.86M
Free Cash Flow per Share
-1.22

Dividends & Yields

NewAmsterdam Pharma Company pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-6.25%
Earnings Yield
-8.20%

Stock Price Statistics

Beta
1.17
52-Week Price Change
-44.70%
50-Day Moving Average
21.53
200-Day Moving Average
29.15
Relative Strength Index (RSI)
47.28
Average Volume (3m)
1.59M

Important Dates

NewAmsterdam Pharma Company upcoming earnings date is Mar 03, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 04, 2026
Next Earnings Date
Mar 03, 2027
Ex-Dividend Date
―

Financial Position

NewAmsterdam Pharma Company as a current ratio of 7.88, with Debt / Equity ratio of 0.03%

Current Ratio
7.88
Quick Ratio
7.88
Debt to Market Cap
0.00
Net Debt to EBITDA
2.02
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, NewAmsterdam Pharma Company has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

NewAmsterdam Pharma Company EV to EBITDA ratio is -9.75, with an EV/FCF ratio of -13.21.

EV to Sales
76.81
EV to EBITDA
-9.75
EV to Free Cash Flow
-13.21
EV to Operating Cash Flow
-13.24

Balance Sheet

NewAmsterdam Pharma Company has $628.24M in cash and marketable securities with $76.00K in debt, giving a net cash position of $628.17M billion.

Cash & Marketable Securities
$628.24M
Total Debt
$76.00K
Net Cash
$628.17M
Net Cash Per Share
$5.24
Tangible Book Value Per Share
$5.08

Margins

Gross margin is 97.84%, with operating margin of -900.07%, and net profit margin of -789.94%.

Gross Margin
97.84%
Operating Margin
-900.07%
Pretax Margin
-785.29%
Net Profit Margin
-789.94%
EBITDA Margin
-787.56%
EBIT Margin
-788.51%

Analyst Forecast

The average price target for NewAmsterdam Pharma Company is $54.70, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$54.70
Price Target Upside
171.60% Upside
Analyst Consensus
Strong Buy
Analyst Count
11
Revenue Growth Forecast
-26.41%
EPS Growth Forecast
16.12%

Scores

Smart Score
7
AI Score
52